loading...| Preferred Name |
allopurinol sodium |
|
| Synonyms |
Apurin |
|
| Definitions |
The sodium form of allopurinol, which is a structural isomer of hypoxanthine. Allopurinol inhibits xanthine oxidase, an enzyme that converts oxypurines to uric acid. By blocking the production of uric acid, this agent decreases serum and urine concentrations of uric acid, thereby providing protection against uric acid-mediated end organ damage in conditions associated with excessive production of uric acid, i.e. the massive cell lysis associated with the treatment of some malignancies. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2564" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2564" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000038452 |
|
| altLabel |
Apurin Caplenal Urbol Alositol Nektrohan Urtias 4-hydroxypyrazolo[3,4-d]pyrimidine Lysuron Lopurin Geapur Dabroson Cosuric Allural Hexanurat BW 56158 Takanarumin 4'-HPP Zyloprim Ketobun-A Zyloric Sigapurol Embarin Allozym Miniplanor Uripurinol Folligan Hamarin Urosin Riball Allo-Puren Anzief sodium allopurinol Apurol Monarch Apulonga Epidropal Cellidrin Bleminol 1,5-dihydro-4H-pyrazolo[3,4-d]pryimidin-4-one monosodium salt 1H-pyrazolo[3,4-d]pyrimidin-4-ol monosodium salt Xanturat Zurinol Bloxanth Ketanrift Aloral Uricemil Ledopur BW-56158 Gichtex Aloprim Adenock Remid Anoprolin Suspendol |
|
| Component of | ||
| cui |
C1449491 C1515909 C1515913 C1515914 C1515903 C1449514 C1254025 C1515915 C1515916 C5441969 C1254031 C1449489 C1515902 C1765317 C1515904 C1449494 C1515921 C1515899 C1515906 C1515907 C1527355 C0875958 C1515910 C0591300 C0591223 C1449499 C0701096 C1449515 C1515920 C4732940 C4087089 C1515901 C1449490 C1515905 C1449517 C1515898 C0701100 C1449513 C1515911 C1515919 C1515908 C1449502 C0002144 C1515918 C0701099 C1515917 C1515912 C0278766 C1515900 |
|
| Date last modified |
2017-10-11 |
|
| definition |
The sodium form of allopurinol, which is a structural isomer of hypoxanthine. Allopurinol inhibits xanthine oxidase, an enzyme that converts oxypurines to uric acid. By blocking the production of uric acid, this agent decreases serum and urine concentrations of uric acid, thereby providing protection against uric acid-mediated end organ damage in conditions associated with excessive production of uric acid, i.e. the massive cell lysis associated with the treatment of some malignancies. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2564" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2564" NCI Thesaurus) |
|
| Legacy PDQ ID |
1107 |
|
| LT |
TRD |
|
| NCI ID |
C2564 |
|
| notation |
CDR0000038452 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
allopurinol sodium |
|
| tui |
T109 T121 |